Brief: Imugene Got Western Institutional Review Board Approval To Commence Phase I Clinical Trial Of Oncolytic Virotherapy Candidate, Vaxinia
23/03/2022 01:17
March 23 (Reuters) - Imugene Ltd IMU.AX :
* GOT WESTERN INSTITUTIONAL REVIEW BOARD APPROVAL TO
COMMENCE
PHASE I CLINICAL TRIAL OF ONCOLYTIC VIROTHERAPY CANDIDATE,
VAXINIA IN USA
Source text for Eikon: ID:nASX2GLrRR
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement